Matches in Nanopublications for { ?s ?p "DDI between Zolpidem and Atazanavir - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed. [drugbank_resource:DB00425_DB01072]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00425_DB01072 label "DDI between Zolpidem and Atazanavir - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed. [drugbank_resource:DB00425_DB01072]" assertion.